AI English summary of an SEC filing — figures as filed
Medtronic MDTMedtronic said Medtronic, Inc. entered into an underwriting agreement on September 15, 2025 to sell 2.950% Senior Notes due 2030 and 4.200% Senior Notes due 2045 to the underwriters, each in the aggregate principal amount of €750,000,000.
Key points
AI summaryMedtronic said Medtronic, Inc. entered into an underwriting agreement on September 15, 2025 to sell 2.950% Senior Notes due 2030 and 4.200% Senior Notes due 2045 to the underwriters, each in the aggregate principal amount of €750,000,000.
The company said the Notes are fully and unconditionally guaranteed on a joint and several basis by Medtronic Luxco and Medtronic plc and are being issued in an underwritten offering pursuant to a registration statement on Form S-3 filed on March 3, 2023.
Medtronic said Medtronic Luxco elected to redeem all €500,000,000 of its outstanding 2.625% Senior Notes due 2025 on September 29, 2025 at a redemption price equal to 100% of the principal amount, plus accrued and unpaid interest to, but not including, the redemption date. The company said Medtronic Luxco's obligation to redeem the notes is conditioned upon the completion of the issuance and sale of the new Notes.
Medtronic said it expects to use the net proceeds from the Offering to repay Medtronic Luxco's 0.000% and 2.625% Senior Notes due 2025. The company added that the financial impact from the Offering and the expected use of proceeds was reflected in Medtronic plc's fiscal year 2026 adjusted earnings per share guidance that it reiterated on August 19, 2025.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Issuance of 2 series of senior notes at €750,000,000 each
Medtronic said Medtronic, Inc. entered into an underwriting agreement on September 15, 2025 to sell 2.950% Senior Notes due 2030 and 4.200% Senior Notes due 2045 to the underwriters, each in the aggregate principal amount of €750,000,000.
Source · Based on the filing body and exhibits
Guarantee structure and registration statement for the issued notes
The company said the Notes are fully and unconditionally guaranteed on a joint and several basis by Medtronic Luxco and Medtronic plc and are being issued in an underwritten offering pursuant to a registration statement on Form S-3 filed on March 3, 2023.
Source · Based on the filing body and exhibits
Decision to redeem all 2.625% senior notes due 2025
Medtronic said Medtronic Luxco elected to redeem all €500,000,000 of its outstanding 2.625% Senior Notes due 2025 on September 29, 2025 at a redemption price equal to 100% of the principal amount, plus accrued and unpaid interest to, but not including, the redemption date. The company said Medtronic Luxco's obligation to redeem the notes is conditioned upon the completion of the issuance and sale of the new Notes.
Source · Based on the filing body and exhibits
Use of net proceeds and fiscal year adjusted earnings per share guidance
Medtronic said it expects to use the net proceeds from the Offering to repay Medtronic Luxco's 0.000% and 2.625% Senior Notes due 2025. The company added that the financial impact from the Offering and the expected use of proceeds was reflected in Medtronic plc's fiscal year 2026 adjusted earnings per share guidance that it reiterated on August 19, 2025.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…